HPGDS and lung adenocarcinoma: As shown in Figure 1A,B, HPGDS exhibited a significantly decreased expression relative to the matched normal tissues in several cancer types, including bladder carcinoma (BLCA), breast cancer (BRCA), colon adenocarcinoma (COAD), lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC), but it was significantly overexpressed in several other cancer types, including GBM, low-grade glioma (LGG), cholangio carcinoma (CHOL), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), and thyroid cancer (THCA).